Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices

Exclusion Criteria

• •1. Pregnant woman (urinary beta-HCG positive at inclusion) or breastfeeding
• •2. Active smoking or ex-smoking for less than 6 months and more than 10 pack-years
• •3. Exacerbation in the 4 weeks preceding first Mepolizumab injection
• •4. Patient who has already been treated with Mepolizumab or another anti-IL-5 or -5R treatment
• •5. Patient currently using a biotherapy indicated in severe asthma other than anti-IL5 or 5R treatments or stopped for less than 2 months
• •6. Treatment underway with another biotherapy not indicated for severe asthma
• •7. Patient participating in other interventional research, excluding routine care research (old regulation) and category 2 research not interfering with primary endpoint analysis
• •8. Other chronic respiratory pathology (bronchiectasis, chronic obstructive pulmonary disease, pulmonary fibrosis, etc.)
• •9. Any other uncontrolled chronic pathology, the presence of which would be considered incompatible with the performance of the study by the investigator
• •10. Patient under guardianship, curatorship or legal protection